PMID- 34435474
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 20
DP  - 2021 Oct
TI  - Alitretinoin in the treatment of cutaneous T-cell lymphoma.
PG  - 7071-7078
LID - 10.1002/cam4.4237 [doi]
AB  - INTRODUCTION: In this survey, we analyzed data from patients suffering from the 
      most common cutaneous T-cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) 
      and Sezary syndrome (SS), treated with the retinoid alitretinoin during a 7-year 
      period at our outpatient department between 2015 and 2020. MATERIALS AND METHODS: 
      We analyzed patient medical records including TNMB stage, side effects under 
      therapy with alitretinoin, time to next treatment (TTNT), and previous photo 
      documentation. RESULTS: A total of 35 patients with MF (n = 28) and SS (n = 7) 
      were included in the study, of whom 69% were male and 31% were female. The mean 
      age of onset was 56 +/- 15 years in MF and 65.4 +/- 10.8 years in SS with 51.4% 
      having early stage (IA-IIA) and 48.6% having advanced stage (IIB-IVA) CTCL. Of 
      these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 
      34.3% experienced progression. Alitretinoin was administered as a monotherapy 
      (25.7%) or combined with five concomitant therapies (74.2%), most frequently with 
      ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often 
      hypertriglyceridemia (20%) was described. CONCLUSION: Considering that nearly two 
      thirds of the CTCL patients treated with alitretinoin showed a response or stable 
      disease, together with a low number of side effects and low cost compared to 
      bexarotene, alitretinoin may be a potential alternative in the treatment of less 
      advanced CTCLs. This survey represents the largest number of recorded therapies 
      with the retinoid alitretinoin in CTCLs in a European patient collective.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Kaemmerer, Till
AU  - Kaemmerer T
AUID- ORCID: 0000-0001-6068-2873
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
FAU - Stadler, Pia-Charlotte
AU  - Stadler PC
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
FAU - Helene Frommherz, Leonie
AU  - Helene Frommherz L
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
FAU - Guertler, Anne
AU  - Guertler A
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
FAU - Einar French, Lars
AU  - Einar French L
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
AD  - Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of 
      Medicine, University of Miami, Miami, Florida, USA.
FAU - Reinholz, Markus
AU  - Reinholz M
AD  - Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210825
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 1UA8E65KDZ (Alitretinoin)
RN  - A61RXM4375 (Bexarotene)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alitretinoin/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Bexarotene/therapeutic use
MH  - Combined Modality Therapy/methods
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lymphoma, T-Cell, Cutaneous/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Mycosis Fungoides/*drug therapy/pathology
MH  - PUVA Therapy
MH  - Sezary Syndrome/*drug therapy/pathology
MH  - Skin Neoplasms/*drug therapy/pathology
PMC - PMC8525105
OTO - NOTNLM
OT  - cancer management
OT  - drug discovery and delivery
OT  - non-Hodgkin's lymphoma
OT  - survival
COIS- None.
EDAT- 2021/08/27 06:00
MHDA- 2022/03/09 06:00
PMCR- 2021/08/25
CRDT- 2021/08/26 06:37
PHST- 2021/07/09 00:00 [revised]
PHST- 2021/05/12 00:00 [received]
PHST- 2021/08/17 00:00 [accepted]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/08/26 06:37 [entrez]
PHST- 2021/08/25 00:00 [pmc-release]
AID - CAM44237 [pii]
AID - 10.1002/cam4.4237 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Oct;10(20):7071-7078. doi: 10.1002/cam4.4237. Epub 2021 Aug 25.